The latest announcement is out from Verona Pharma (VRNA).
Verona Pharma plc has announced FDA approval of Ohtuvayre (ensifentrine) for treating chronic obstructive pulmonary disease (COPD) in adults, marking a significant milestone for the company. This innovative treatment, which uniquely combines bronchodilator and anti-inflammatory effects, promises ease of use through a standard jet nebulizer. Ohtuvayre, set to hit the market in Q3 2024, is expected to be distributed exclusively via accredited specialty pharmacies, making it a noteworthy development for investors tracking pharmaceutical innovations and market entries.
Find detailed analytics on VRNA stock on TipRanks’ Stock Analysis page.
